PRTA - רווח נקי למניה (EPS TTM) Prothena Corp

Prothena Corporation (PRTA) relies on powerful patents in Alzheimer's therapy and alliances with industry behemoths. Net income per share over the last four quarters demonstrates local dynamics, where the value -0.47 describes the current level. However, colossal R&D expenditures and strict FDA oversight create barriers, while geopolitical tensions in the US and Ireland complicate component logistics.

Retaining key neurobiologists through stock option programs directly impacts capital dilution, which is critical when calculating net earnings per share for Prothena Corporation (PRTA). By analyzing the rolling 12-month EPS, an investor sees the final annual financial result divided by the number of shares, where steady growth confirms effective resource management and the minimization of investment freeze risks.